Protalix BioTherapeutics, Inc PLX was a big mover last session, as the company saw its shares rise 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $0.56-$0.63 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen no estimate revisions over the past one month, and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Protalix currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Protalix BioTherapeutics, Inc. Price and Consensus
A better ranked stock in the Medical - Biomedical and Genetics industry is Axovant Sciences Ltd.AXON which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.